Syneos Health (Syneos Health) Cash, Cash Equivalents, Marketable Securities : $82 Mil (As of Jun. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Syneos Health Cash, Cash Equivalents, Marketable Securities?

Syneos Health's quarterly cash, cash equivalents, marketable securities declined from Dec. 2022 ($112.00 Mil) to Mar. 2023 ($110.94 Mil) but then stayed the same from Mar. 2023 ($110.94 Mil) to Jun. 2023 ($82.17 Mil).

Syneos Health's annual cash, cash equivalents, marketable securities declined from Dec. 2020 ($272.17 Mil) to Dec. 2021 ($106.48 Mil) but then increased from Dec. 2021 ($106.48 Mil) to Dec. 2022 ($112.00 Mil).

Syneos Health Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Syneos Health's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Syneos Health Cash, Cash Equivalents, Marketable Securities Chart

Syneos Health Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

155.93

163.69

272.17

106.48

112.00

Syneos Health Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															105.88	170.00	112.00	110.94	82.17

Syneos Health Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Syneos Health (NAS:SYNH) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Syneos Health Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Syneos Health's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Syneos Health (Syneos Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Syneos Health Inc (NAS:SYNH) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

1030 Sync Street, Morrisville, NC, USA, 27560-5468

Website

https://www.syneoshealth.com

Syneos is a global contract research and outsourced commercialization organization that provides services to pharmaceutical and biotechnology firms. Its clinical solutions segment offers early- to late-stage clinical trial support that ranges from specialized staffing models to strategic partnerships that oversee nearly all aspects of a drug program, while the company's commercialization solutions includes outsourced sales, consulting, public relations, and advertising services.

Executives

Michael J. Bonello	officer: Chief Financial Officer	4130 PARKLAKE AVENUE, SUITE 400, RALEIGH NY 27612
Stanford Rudnick	officer: See remarks	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468
Christian Tucat	officer: Chief Business Officer	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560-5468
Michael Lee Brooks	officer: See remarks	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Jonathan Olefson	officer: General Counsel & Corp Secty	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Michelle Keefe	officer: Pres., Commercial Solutions	C/O SYNEOS HEALTH,INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Jason M. Meggs	officer: Chief Financial Officer	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Donna Hildebrand Kralowetz	officer: SVP, Chief Accounting Officer	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
Matthew E. Monaghan	director	ONE INVACARE WAY, ELYRIA OH 44035
Alfonso G Zulueta	director	4925 INDIANA AVE, LISLE IL 60532
Barbara W. Bodem	director	C/O DENTSPLY SIRONA INC, 13320 BALLANTYNE CORPORATE PLACE, CHARLOTTE NC 28277
Linda S Harty	director	MEDTRONIC PLC, 710 MEDTRONIC PARKWAY NE, LC-150, MINNEAPOLIS MN 55432
Alistair Macdonald	officer: Chief Operating Officer	C/O SYNEOS HEALTH, INC., 1030 SYNC STREET, MORRISVILLE NC 27560
David S. Wilkes	director	ONE BAXTER PARKWAY, DEERFIELD IL 60015
Advent International Corp/ma	10 percent owner	800 BOYLSTON STREET SUITE 3300, BOSTON MA 02199